.Attributes Medicine, Posted online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) therapy of individuals along with HER2+ innovative bosom cancer cells and also energetic or secure human brain metastases showed regular intracranial activity as well as wide spread efficiency of T-DXd.